Small molecule · Inhibitor of complement factor B (CFB) · developed by Novartis
Iptacopan is an orally available small-molecule inhibitor of complement factor B. It binds factor B and prevents formation of the alternative pathway C3 convertase, limiting C3 cleavage and downstream complement activation. It is studied in atypical hemolytic uremic syndrome and lupus nephritis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05795140 | Phase 3 | Atypical Hemolytic Uremic Syndrome | Recruiting | NVS |
| NCT05268289 | Phase 2 | Lupus Nephritis | Terminated | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atypical Hemolytic Uremic SyndromeLupus Nephritis
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →